Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C.
direct-acting antiviral
hepatitis C virus
hepatocellular carcinoma
sofosbuvir
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Sep 2020
11 Sep 2020
Historique:
received:
23
07
2020
revised:
03
09
2020
accepted:
09
09
2020
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antivirals (DAAs). However, it remains unclear if DAAs themselves have an influence on or facilitate the development of HCC. This multicenter cohort study included CHC patients without a history of HCC who achieved HCV elimination by DAAs. Cohorts of 835 patients treated with a sofosbuvir (SOF)-based regimen and 835 treated with a SOF-free regimen were matched 1:1 by propensity scoring with nine variables to evaluate differences in HCC incidence. The median observation period was 3.5 years. Sixty-nine cases of HCC were found during 5483.9 person-years (PY) over the entire follow-up period. The annual incidence was similar for both groups (SOF-based 1.25 and SOF-free 1.27 per 100 PY, respectively: adjusted hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.75-2.12,
Identifiants
pubmed: 32933027
pii: cancers12092602
doi: 10.3390/cancers12092602
pmc: PMC7563479
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : JSPS KAKENHI
ID : 20K08820
Références
Gastroenterology. 2018 Aug;155(2):411-421.e4
pubmed: 29655836
Oncogene. 2006 Jun 26;25(27):3787-800
pubmed: 16799620
Hepatology. 2014 Apr;59(4):1577-90
pubmed: 24677197
Hepatol Commun. 2020 Apr 06;4(6):904-915
pubmed: 32490325
Hepatology. 2017 Mar;65(3):804-812
pubmed: 28012259
Apoptosis. 2013 Nov;18(11):1291-1305
pubmed: 23892916
Liver Int. 2018 Feb;38 Suppl 1:139-145
pubmed: 29427487
J Hepatol. 2017 Dec;67(6):1204-1212
pubmed: 28802876
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Gastroenterology. 2018 Nov;155(5):1436-1450.e6
pubmed: 30031138
J Hepatol. 2018 Oct;69(4):810-817
pubmed: 29940268
J Hepatol. 2020 May;72(5):839-846
pubmed: 31790766
Cancers (Basel). 2020 May 26;12(6):
pubmed: 32466400
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132
pubmed: 28404069
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Gastroenterology. 2018 Feb;154(3):515-517.e3
pubmed: 29102620
J Infect Dis. 2020 Jun 25;:
pubmed: 32584386
J Hepatol. 2020 Mar;72(3):472-480
pubmed: 31629779
Gastroenterology. 2011 Jul;141(1):141-9
pubmed: 21440548
J Gastroenterol. 2017 Jul;52(7):845-854
pubmed: 27913920
Gastroenterology. 2019 Jan;156(2):446-460.e2
pubmed: 30367836
Expert Rev Clin Pharmacol. 2012 Jul;5(4):347-50
pubmed: 22943113
Clin Infect Dis. 2019 Nov 28;:
pubmed: 31777940
J Transl Med. 2019 Aug 28;17(1):292
pubmed: 31462268
Oncotarget. 2018 Jun 1;9(42):26868-26883
pubmed: 29928490
Pharmacol Ther. 2018 Mar;183:118-126
pubmed: 29024739
J Hepatol. 2019 Sep;71(3):473-485
pubmed: 31096005
Hepatology. 2018 Sep;68(3):1010-1024
pubmed: 29604220
Cells. 2020 Apr 17;9(4):
pubmed: 32316635
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Aliment Pharmacol Ther. 2018 Jan;47(1):104-113
pubmed: 29035002
Cell Cycle. 2018;17(7):903-916
pubmed: 29633904